PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Immunol. Author manuscript; available in PMC Mar 29, 2011.
Published in final edited form as:
PMCID: PMC3066095
NIHMSID: NIHMS281169
Recovery from Cyclophosphamide-Induced Lymphopenia Results in Expansion of Immature Dendritic Cells Which Can Mediate Enhanced Prime-Boost Vaccination Antitumor Responses In Vivo When Stimulated with the TLR3 Agonist Poly(I:C)1
Mohamed L. Salem,*2 C. Marcela Díaz-Montero,* Amir A. Al-Khami,* Sabry A. El-Naggar,* Osama Naga,* Alberto J. Montero, Ahmed Khafagy,§ and David J. Cole*
*Department of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425
Department of Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425
Zoology Department, Faculty of Science, Tanta University, Egypt
§Microbiology Department, Faculty of Veterinary Medicine, Suez Canal University, Egypt
2Address correspondence and reprint requests to Dr. Mohamed L. Salem, Department of Surgery, Medical University of South Carolina, Charleston, SC 29425. salemm/at/musc.edu
Recent preclinical studies suggest that vaccination following adoptive transfer of CD8+ T cells into a lymphopenic host can augment the therapeutic antitumor responses of the transferred cells. However, the mechanism by which the lymphopenic microenvironment benefits Ag-specific CD8+ T cell responses remains elusive. We show herein that induction of lymphodepletion by a single 4 mg cyclophosphamide (CTX) treatment induces a marked expansion of immature dendritic cells (DCs) in the peripheral blood on days 8–16 post-CTX (termed restoration phase). In vitro, these DCs were functional, because they showed normal phagocytosis and effective Ag presentation capability upon activation. In vivo, administration of the TLR3 agonist poly(I:C) at the peak of DC expansion (day 12 postlymphopenia) induced inflammatory cytokine production and increases in the number of activated DCs in lymph nodes. Importantly, boosting with gp10025–33 melanoma peptide combined with poly(I:C) 12 days after an initial priming with the same regimen significantly increased the expansion and the antitumor efficacy of adoptively transferred pmel-1 CD8+ T cells. These responses were abrogated after depletion of activated DCs during Ag boosting. In conclusion, our data show that CTX treatment induces, during the restoration phase, expansion of immature DCs, which are functional and can be exploited in vivo to foster more effective antitumor adoptive immunotherapy strategies.
Recent studies have shown that preconditioning a host with lymphodepletion regimens such as total body irradiation (TBI)3 or chemotherapy (e.g., cyclophosphamide (CTX)) can effectively augment the antitumor efficacy of adoptively transferred T cells in response to vaccination (16). Suggested mechanisms underlying this effect include enhanced engraftment and survival of the transferred T cells by creation of an immunological “niche” (7) with induction of survival cytokines (8, 9); elimination of regulatory CD4+CD25+ T cells, NKT cells, and myeloid-derived suppressor cells (3, 1012); and depletion of endogenous cells that compete with the transferred T cells for cytokines “cytokine sink” (7, 8, 13). Recent studies suggest, however, that these mechanisms might not be the principal means by which lymphodepletion regimens augment adoptive immunotherapy (4, 1417). Moreover, these mechanisms have been investigated during the lymphopenic phase, and few studies addressed the role of cellular components that might be altered at the restoration phase (in which the host recovers from the induced lymphopenia; days 5–18). Therefore, it is relevant to test whether additional mechanisms are in effect during the lymphopenic or the restoration phases after lymphodepletion.
Given the importance of understanding the precise mechanisms underlying the beneficial effects of lymphodepletion on the clinical application of immunotherapy-based treatment regimens, we have addressed the role of different host mediators during CTX-induced lymphodepletion. Using the OT-1 transgenic (Tg) TCR model, we have recently reported that the adoptive transfer of CD8+ T cells at the lymphopenic phase after CTX treatment resulted in dramatic increases in postvaccination T cell responses, including enhanced expansion and function, and delayed contraction of adoptively transferred CD8+ T cells. These effects were associated with rapid activation of dendric cells (DCs) in the liver and spleen during this early phase of lymphopenia (days 1–4) (14). Earlier studies have also reported rapid activation of DCs and follicular DCs in the spleen and lymph nodes (LNs) of mice rendered lymphopenic by TBI (3) or CTX (18, 19). This rapid activation of DCs during the lymphopenic phase has been suggested to be due to the rapid systemic release of LPS in response to mucosal damage after lymphopdepletion (3). Further, we reported that the beneficial effects of CTX to OT-1 T cell responses were dependent on the presence of CD11b-expressing cells (14), indicating to the possible significance of DCs during the lymphopenic phase. Wrzesinski et al. have reported that using a myeloablative (rather than nonmyeloablative) approach, coupled with subsequent hematopoietic stem cell transplantation, can render adoptively transferred pmel-1 T cells independent of a requirement for prior in vitro activation. This observation was felt to be most likely due to enhanced MHC class I-restricted Ag presentation by elements of the transplanted bone marrow (BM) (4). To directly understand the role of DCs, we focused our present studies on evaluating the numbers, phenotype, and function of DCs at the restoration phase postlymphodepletion induced by CTX treatment.
With our most recent studies, we have made the interesting observation that CTX treatment can induce a substantial expansion of biologically functional immature DCs during the restoration phase, peaking on day 12. Activation of this large pool of DCs by the TLR3 ligand (TLR3L) poly(I:C) resulted in their activation and the appearance of activated CCR7+ DCs in LNs. Furthermore, boosting with peptide/poly(I:C) at the peak of this DC expansion (day 12 postdepletion) after an initial Ag priming led to an enhanced CD8+ T cell antitumor response in the tolerogenic pmel-1 TCR Tg mouse model. Our data would suggest a novel rationale for the design of cancer immunotherapy in the clinical setting based on targeting DCs at certain phases after application of lymphodepletion regimen.
Mice
B6.SJL (Ly5.1), C57BL/6 (Ly5.2; B6), OT-1 and pmel-1 TCR Tg (B6 background), and CD11c-diphtheria toxin receptor (DTR) Tg mice (B6 background) were purchased from The Jackson Laboratory. OT-1 mice were bred with wild type B6.SJL mice to generate Ly5.1+/Ly5.1+ mice heterozygous for the OT-1 TCR (Vα2/Vβ5) transgene, which was confirmed by flow cytometry with mAb specific for Vα2 and Vβ5. CD8+ T cells in OT-1 mice recognize the MHC-I OVA albumin peptide SIINFKEL (OVAp). Pmel-1 (Ly5.2) mice were bred with Ly5.1 wild type mice to generate Ly5.1 mice heterozygous for the pmel-1 TCR Vα1/Vβ13 transgene. The transgene expression was confirmed by PCR analysis. CD8+ T cells expressing the Vα1/Vβ13 TCR specifically recognize the H-2Db-restricted human gp10025–33 epitope (KVPRNQDWL: gp10025–33). This peptide represents an altered form of the murine gp10025–33 (EGSRNQDWL) with improved binding to the MHC class-I. All animals were housed under specific pathogen-free conditions in accordance with institutional and federal guidelines at the Medical University of South Carolina.
Cell lines, Abs, and reagents
B16 melanoma (H2Kb) cells were maintained in complete RPMI 1640 medium. Anti-CD16/CD32, and FITC-, PE-, APC-, and cychrome-conjugated mAbs were purchased from Pharmingen and eBioscience. Human gp10025–33 EGSRNQDWLL melanoma and SIINFEKL OVA peptides (American Peptide Company) were dissolved in 10% DMSO (Sigma) and diluted in PBS. GM-CSF and IL-4 (R&D Systems) were stored as a lyophilized powder at −20°C, and reconstituted immediately before use in 0.1% BSA in PBS. CTX, diphtheria toxin (DTx; Sigma), and DQ-OVA (Invitrogen) were reconstituted in PBS and frozen until used. The TLR3L poly(I:C) was purchased from InvivoGen.
Flow cytometry
Mice were bled from the retro-orbital plexus, and blood samples were then processed for VetScan HM5 Hematology (Abaxis) to assess the total count of peripheral blood leukocytes (PBL). Spleen and LN single-cell suspensions were prepared and counted as previously described (20). For flow cytometry, fresh cells (0.5–1 × 106) were treated with anti-CD16/CD32 for 5 min on ice, stained with the indicated conjugated mAbs, and incubated for 30 min on ice. The cells were washed twice and resuspended in 0.3 ml of 0.5% BSA, 0.02% sodium azide solution. Cells were then washed, and analyzed by flow cytometry using the Cell Quest software package (BD Biosciences). The absolute numbers of different cell populations in each compartment were calculated as: % cells from flow cytometry × total number of cells/100.
Phagocytic function of DCs
Mice were bled and the PBL were prepared, incubated with FITC-labeled dextran (Sigma) for 1 h at 37°C or on ice as negative control. Then cells were washed extensively and stained with anti-CD11c and anti-CD11b mAbs, and the numbers of FITC+ DCs were analyzed by flow cytometry as described before (21).
Ag-presenting function of DCs
DCs (CD11c+CD11b+) were sorted by flow cytometry from the peripheral blood samples pooled from 20 mice after staining the samples with anti-CD11c and anti-CD11b mAbs for 30 min at 4°C. Sorted cells were washed and resuspended in RPMI 1640 medium and cultured in 6-well plate for 2 days in RPMI 1640 medium containing GM-CSF and IL-4 (10 ng/ml each). DCs were irradiated, pulsed with 1 µg/ml OVAp for 2 h at 37°C, washed three times, and then cocultured (1 × 104) with purified naive OT-1 cells (1 × 105) for 3 days. Cultures were pulsed with thymidine for the last 18 h, and then cells were harvested to measure thymidine uptake by γ-counter (22).
CTX preconditioning, adoptive T cell transfer, and vaccination
Recipient wild type naive Ly5.2 mice were treated with PBS or 4 mg/mouse CTX (14, 23) and adoptively transferred 1 day later by lateral tail vein injection with one million of naive pmel-1 Ly5.1 cells. The mice were then vaccinated with s.c. injection of 100 µg/mouse gp10025–33 melanoma peptide with or without 200 µg/mouse poly(I:C) on day 2 and/or day 12 after PBS or CTX treatment. The mice were bled and killed at multiple time points to analyze the expansion and contraction of pmel-1 cells. When mentioned, CD11c-DTR Tg mice were treated with single i.p. injection of 90 ng/kg DTx, as previously described (24), to deplete DCs.
Tumor challenge
Naive B6 mice were challenged with s.c. injection of 2.5 × 105 fresh B16 tumor cells. Ten days after tumor inoculation, mice were treated with PBS or CTX and then adoptively transferred with naive pmel-1 cells followed by vaccination at the indicated time points. Tumor growth was measured by caliper every 3 days and the tumor surface area (mm2) was calculated by length × width. Survival of tumor bearing mice was also recorded.
Statistics
Statistical analyses were performed using the Student’s t test. Log-rank nonparametric analysis using GraphPad Prism (GraphPad Software) was used to graph and analyze the survival data. All p values were two sided, with p < 0.05 considered significant.
CTX treatment induces DC expansion with immature phenotype during the restoration phase
Consistent with previous studies (12, 16, 25), we found that single i.p. injection of CTX induced rapid lymphopenia (days 1–5) in the peripheral blood (Fig. 1A, left panel), spleen, and BM (Fig. 1A, right panel) followed by a restoration phase, in which the cellular components started to recover from lymphopenia. The restoration from lymphopenia in the spleen and BM was observed on day 6 post-CTX treatment. The lymphodepletion in PBL, however, was much more prolonged and hardly reached the basal level by day 18. In all experiments, control mice were treated with PBS and the levels of cells present are represented as day 0 in the figures. Despite the fact that a significant lymphopenia was still persistent in the peripheral blood, substantial increases in the relative numbers of DCs (CD11c+CD11b+) were observed in this compartment from days 9–14 as compared with PBS-treated mice (p = 0.0005) (Fig. 1B), peaking on day 11–12 post-CTX treatment and representing ~25% of total PBL. When PBL harvested 12 days after CTX treatment was incubated overnight in serum-free medium, it showed numerous adherent DCs as compared with PBL harvested from PBS-treated mice (Fig. 1C). The increase in the relative numbers of DCs in PBL on day 12 post-CTX treatment was correlated with a significant increase in the absolute numbers of these cells (greater than 2-fold, p = 0.007) (Fig. 1D, left panel), which was more pronounced when it was calculated per one million PBL (Fig. 1D, right panel). Of note, expansion of DCs was also found in the spleen of CTX-treated mice; the DC expansion was dose- and Flt3L-dependent (M. L. Salem, A. A. AL-Khami, S. A. EL-Naggar, C. M. Díaz-Montero, Y. Chen, O. Naga, and D. J. Cole, manuscript in preparation). To understand whether DC expansion in the peripheral blood was due to the proliferation of DC progenitors in BM or in the blood, we analyzed the proliferation of DCs in these compartments by BrdU incorporation assay at multiple time points post-CTX treatment. As shown in the Supplementary Fig. 1, A (PBL) and B (BM),4 the relative numbers of BrdU+CD11c+CD11b+ DCs were higher only in BM, but not in the blood, as compared with control mice when analyzed 2 days post-CTX treatment. By day 6, however, the relative numbers of BrdU+ DCs in the blood of CTX-treated mice were high and those in BM were low. On the whole, the increase in the numbers of the proliferating DCs in BM at an early time point following CTX treatment, together with the appearance of BrdU+ DCs in the blood on day 6 (i.e., at least 3 days before the initiation of DC expansion), would suggest that DC expansion in the peripheral blood is, at least in part, due to the migration of proliferating DC progenitor from BM to the circulation.
FIGURE 1
FIGURE 1
CTX treatment induced increases in the numbers of circulating cDCs during the restoration phase. A, Female naive B6 mice (n = 4/group) were i.p. treated with PBS (represented as day 0) or CTX (4 mg/mouse) and killed at the indicated time points. The total (more ...)
DCs in the peripheral blood can be categorized into conventional DCs (cDCs; CD11chighCD11bhighGr.1lowB220low) and plasmacytoid DCs (pDCs; CD11chighCD11blowGr.1highB220high) (2628). To determine which DC subset was expanded in response to CTX treatment, PBL from PBS- or CTX-treated mice were analyzed for the presence of cDC and pDC specific markers (Supplementary Fig. 2).4 Blood from PBS-treated mice showed ~4% cDCs vs ~1–2% pDCs. By contrast, blood from CTX-treated mice showed ~25–30% cDCs and ~2–4% pDCs (Fig. 1E). We then analyzed the activation phenotype of DCs at multiple time points after CTX treatment. Consistent with previous studies (14, 29), we found that CTX treatment induced an up-regulation of CD80 expression in DCs on day 3 posttreatment. From day 3 onward, however, expression of CD80 (Fig. 2A) and CD40, CD86, and MHC class-II (data not shown) showed low levels in DCs (Fig. 2A). In conclusion, CTX-induced expansion of DCs in circulation during the recovery phase favored the generation of cDCs bearing an immature phenotype.
FIGURE 2
FIGURE 2
CTX treatment induced an expansion of functional cDCs with immature phenotype. A, Naive B6 mice (n = 4/group) were treated i.p. with PBS or CTX, bled at the indicated time points, and the PBL were stained with anti-CD11c, anti-CD11b, and anti-CD80 mAbs (more ...)
Post-CTX expanded DCs are biologically functional
To address whether post-CTX expanded DCs were functional, we assessed their phagocytic and Ag presentation capabilities, which are the hallmarks of functional immature and mature DCs, respectively. Using the FITC-labeled dextran in vitro phagocytosis assay, we found that the phagocytic capability of circulating DCs on day 12 after CTX treatment did not significantly differ from those of circulating DCs in PBS-treated control mice (Fig. 2B, lower panel). Cells incubated with FITC-dextran-FITC at 4°C, as negative control, did not show phagocytosis (Fig. 2B, upper panel). We further tested whether DCs could uptake and process Ag in vivo, using DQ-OVA as a model Ag. DQ-OVA is a fluorogenic reagent which is undetectable in its unprocessed form because of autoquenching, but becomes fluorescent upon entry into acidic endosomal cellular compartment (30). PBS- and CTX-treated mice were s.c. challenged with DQ-OVA on day 12 after treatments. DCs from PBS- and CTX-treated mice acquired similar amounts of DQ-OVA (Fig. 2C). Then, we assessed the Ag presenting capability of DCs. Thus, DCs (CD11c+CD11b+) were sorted from PBL pooled from 20 mice after 12 days of PBS or CTX treatment. Similar numbers of sorted DCs from PBS- and CTX-treated mice were matured by incubation with GM-CSF/IL-4 for 2 days, pulsed with OVAp, and cocultured with naive OT-1 cells (1:1 ratio) for 3 days. Fig. 2D shows that DCs sorted (>98% pure) 12 days post-CTX treatment were able to more efficiently present OVAp to OT-1 cells than DCs purified from PBS-treated mice, as evidenced by the proliferation levels of OT-1 cells. OVAp-pulsed DCs, generated in vitro from BM of naive B6 mice in the presence of GMCSF and IL-4, were used as a positive control APCs (data not shown).
Triggering TLR3 signaling at the peak of post-CTX DC expansion induced an inflammatory milieu, resulting in appearance of activated DCs in LNs
Because post-CTX expanded DCs at the restoration phase expressed an immature phenotype (Fig. 2), we attempted to activate these cells with TLR ligands (TLRL), which are potent activators of innate immune cells, in particular DCs (3138). We have recently reported that the TLR3L poly(I:C) is a potent adjuvant for CD8+ T cell responses (20, 38, 39), and that DCs (CD11c+CD11b+) sorted from PBL harvested 12 days after PBS and CTX treatments showed similar expression levels of TLR3 (data not shown). Therefore, we used poly(I:C) to activate CTXexpanded cDCs. It was found that administration of poly(I:C) on day 12 after CTX treatment induced a significant decrease in the number of cDCs in PBL, coinciding with a significant increase in the number of these cells in LNs compared with CTX-treated controls (Fig. 3A). Of note, poly(I:C) did not alter the numbers of DCs in blood, spleen, or LNs of naive mice (data not shown). The cDCs that appeared in the LNs expressed an activation phenotype, as evidenced by the expression of high levels of CD40 and CD80 (Fig. 3B). Interestingly, after poly(I:C) treatment, cDCs in PBL of CTX-treated mice expressed low levels of CCR5 and CCR7, but those in LNs and spleen expressed low levels of CCR5 and higher levels of CCR7 (Fig. 3C), which is essential for DCs to migrate to LNs (40).
FIGURE 3
FIGURE 3
Triggering TLR3 signaling at the peak of post-CTX DC expansion resulted in appearance of activated DCs in LNs. A, Naive B6 mice (n = 4/group) were treated with PBS or CTX and i.p. injected 12 days later with PBS or 200 µg/mouse poly(I:C). Mice (more ...)
To address how post-CTX expanded DCs were activated after poly(I:C) treatment, we measured the serum levels of inflammatory cytokines after injection of poly(I:C) on day 12 post-PBS- or CTX-treatment. Consistent with our recent report (38), higher levels of TNF-α, MCP-1, IL-6, and IFN-γ were induced in sera collected 4 h after poly(I:C) administration into PBS-treated mice (Fig. 4). The levels of these cytokines, however, were higher in the sera of CTX-treated mice than in control mice. These data would suggest that poly(I:C) induces activation of CTX-expanded DCs through creation of an inflammatory milieu even in the absence of active vaccination. To determine whether DCs or NK cells are the source of these cytokines, we injected poly(I:C) into DTR transgenic mice (in which DCs were depleted by i.p. injection of 90 ng/Kg of DTx) or into mice depleted of NK cells by i.p. injection of 50 µl/mouse anti-asialo GM1 Ab 24 h before poly(I:C) injection. As shown in Fig. 4, depletion of DCs abrogated the poly(I:C)-mediated induction of TNF-α, MCP-1, IL-6, and IFN-γ after poly(I:C) treatment. Depletion of NK cells, however, only abrogated the poly(I:C)-mediated induction of IFN-γ. These results indicate that DCs are a significant contributor to the inflammatory cytokines induced after administration of poly(I:C) at the peak of post-CTX DC expansion.
FIGURE 4
FIGURE 4
Triggering TLR3 signaling at the peak of post-CTX DC expansion created an inflammatory milieu dependent on DCs. Wild-type (n = 4/group) or DTR Tg (n = 3/group) B6 mice were treated with PBS or CTX and i.p. injected 12 days later with PBS or 200 µg/mouse (more ...)
Vaccination with gp10025–33/poly(I:C) at the peak of post-CTX DC expansion augmented CD8+ T cell responses to self tumor Ag
To evaluate the significance of post-CTX DC expansion, we sought to determine whether it could affect T cell responses to self tumor Ag in vivo. To this end, we used the preclinical TCR Tg pmel-1 model. Thus, naive Ly5.2 mice were challenged with B16 tumor and treated 10 days later (the time point when the tumor was established) with PBS or CTX and adoptively transferred with 1 × 106 naive Ly5.1 pmel-1 cells followed by vaccination with gp10025–33 ± poly(I:C) at day 12 post-CTX administration. Ag priming with gp10025–33 alone did not induce pmel-1 cell expansion as measured by the low levels of the relative and absolute numbers of pmel-1 cells in PBL 5 days post vaccination. Ag priming with gp10025–33/poly(I:C) in CTX-, but not PBS-, treated mice marginally enhanced the expansion of pmel-1 cells (Fig. 5A). The same results were seen when adoptive transfer of pmel-1 cells and gp10025–33/poly(I:C) vaccination was performed on day 2 post-CTX treatment (data not shown). Given this low expansion of pmel-1 cells in response to a single vaccination, we sought to perform vaccination with gp10025–33/poly (I:C) at both the lymphopenic and restoration phases (prime-boost regimen). Thus, mice were challenged with B16 tumor and treated with PBS or CTX as above and then primed and boosted with gp10025–33 ± poly(I:C) on days 2 and 12, respectively, posttreatments. Boosting with gp10025–33/poly(I:C) in CTX-, but not PBS-, treated mice resulted in significant increases in the relative (shown above each column) and absolute numbers of pmel-1 cells analyzed in PBL (Fig. 5B, upper panel), LNs (Fig. 5B, lower panel), and spleen (data not shown) on day 3 after Ag boosting. These results indicate that activation of post-CTX expanded DCs could enhance the activity of vaccine primed pmel-1 cells better than naive cells, suggesting that a prime-boost vaccination regimen would be an effective approach to exploit the significance of CTX-induced DC expansion.
FIGURE 5
FIGURE 5
Boosting with peptide/poly(I:C) at the peak of post-CTX DC expansion is essential to augment CD8+ T cell response to self-tumor Ag. A, Naive Ly5.2 mice were inoculated with 2.5 × 105 B16 cells in their right flank and treated 10 days later (the (more ...)
Augmentation of CD8+ T cell expansion after gp10025–33/poly(I:C) prime-boost regimen coincides with a temporal appearance of activated DCs in LNs
To determine whether the poly(I:C)-induced expansion of pmel-1 cells in CTX-treated mice was associated with trafficking of post-CTX expanded DCs into LNs, we analyzed the distribution of DCs 3 days after boosting with the same regimen described in Fig. 5B. As expected at this time point (day 15 post-CTX treatment), the relative and absolute numbers of DCs in PBL of CTX-treated mice were still higher than control mice (Fig. 5C). Interestingly, this increase in DC numbers in PBL of CTX treated mice were further accentuated upon vaccination with gp10025–33 but not after vaccination with gp10025–33/poly(I:C), which was associated with a marked increase in the numbers of DCs in LNs. These results suggest the migration of DCs from blood to lymphoid compartments such as LNs upon their activation with poly(I:C). A selective increase in the percentage and absolute numbers of CD8α+ cDCs over CD8α cDCs was observed in LNs (Fig. 5D) and spleen (data not shown) of CTX-treated mice boosted with gp10025–33/poly(I:C). To test whether this selective effect of poly(I:C) on the number of these subsets of cDCs in LNs correlates with a selective effect on their activation phenotype, we repeated the experiment above and analyzed the activation phenotype of CD8α cDCs and CD8α+ cDCs in LNs. We found that vaccination with gp10025–33/poly(I:C) induced significant up-regulation in the expression of CD40 in CD8α cDCs and CD8α+ cDCs in LNs and spleen, with more noticeable effect in CTX- vs PBS-treated mice (Fig. 6, A and B). The expression levels of CD86 were also increased in CD8α and CD8α+ cDCs in LNs (Supplementary Fig. 3).4 Similar results were observed in the spleen (Fig. 6B). We then asked which of the cDC subsets in LNs and spleen is capable of Ag uptake. To this end, PBS- and CTX-treated mice were s.c. injected with DQ-OVA ± poly(I:C) on day 12 after treatments and killed 2 days later to assess the capability of CD8α cDCs and CD8α+ cDCs in LNs and spleen to uptake DQ-OVA. Consistent with previous studies (41), we found that the number of DQ-OVA+ CD8α+ cDCs in LNs was higher than DQ-OVA+ CD8α cDCs; opposite profile of DQ-OVA uptake by these cells was observed in spleen (Fig. 6C). Poly(I:C) treatment did not alter the Ag uptake profile. Taken together, the augmented systemic pmel-1 cell expansion in response to boosting with gp10025–33/poly(I:C) at the peak of post-CTX DC expansion could be attributed to the temporal increase in the number of activated DCs in secondary lymphoid tissues, in particular LNs.
FIGURE 6
FIGURE 6
Boosting with peptide/poly(I:C) at the peak of post-CTX DC expansion increases the number of activated DCs in LNs. Mice were treated with PBS or CTX and adoptively transferred with 1 × 106 un-fractionated naive spleen cells from Ly5.1 donor pmel-1 (more ...)
Depletion of DCs abrogates the augmented pmel-1 T cell responses to prime-boost vaccination
To directly test our hypothesis of the critical role of post-CTX-activated DCs in mediation of CD8+ T cell expansion, DCs were depleted before Ag boosting using CD11c-DTR Tg mouse model, which is based on a system that allows the conditional ablation of CD11chigh cDCs, but not pDCs. DTR expression in these mice is driven by a DNA fragment flanking the Itgax gene, which encodes the αx subunit of the CD11c integrin (30). Thus, Ly5.2 wild type and CD11c-DTR Tg mice were treated with PBS or CTX, adoptively transferred one day later with Ly5.1 pmel-1 cells, and then primed and boosted with gp10025–33 ± poly(I:C) on days 2 and 12, respectively, posttreatments. The CD11c-DTR Tg mice were treated i.p. with DTx one day before Ag boosting to deplete DCs. The mice were killed 2 days later (day 14 post-CTX treatment) to analyze the numbers of DCs and the expansion of pmel-1 cells. As shown in Fig. 7A, treatment with DTx effectively depleted CD11c+CD8+ (upper right of the quadrant) and CD11c+CD8 (upper left of the quadrant) in blood, spleen, and LNs of both PBS- and CTX-treated CD11c-DTR Tg mice. The relative and absolute numbers of DCs in the spleen and LNs before and after DTx injection into control and CTX-treated mice are shown in Fig. 7, B and C. Interestingly, depletion of DCs in CTX-treated mice markedly abrogated the expansion of pmel-1 cells, as indicated by the marked decreases in the relative and absolute numbers of pmel-1 cells in spleen, LNs (Fig. 7D), and PBL (data not shown). Of note, treatment of wild type mice with DTx did not alter the magnitude of pmel-1 cell expansion (data not shown). These data would indicate that post-CTX expanded DCs significantly contributed to the beneficial effects of CTX preconditioning regimen to the responses of effector cells to Ag recall.
FIGURE 7
FIGURE 7
Depletion of DCs before peptide/poly(I:C) boosting at the peak of expansion abrogates the augmented T cell responses post-CTX therapy. Wild type and CD11c-DTR Tg Ly5.2 mice (three mice/group) were treated with PBS or CTX and then adoptively transferred (more ...)
Boosting with peptide/poly(I:C) at the peak of post-CTX DC expansion is essential to establish a therapeutic antitumor immunity to self tumor Ag
We finally evaluated the therapeutic antitumor efficacy of our treatment regimen consisting of CTX preconditioning, adoptive transfer of naive pmel-1 cells, and prime-boost vaccination with gp10025–33/poly(I:C) at the lymphopenic and restoration phases. To this end, we tested the effects of one vs two vaccinations against established B16 tumor. Thus, B6 mice were challenged with B16 tumor. Tumors were allowed to grow for 10 days, and the mice were then treated with PBS or CTX. One day later, the mice were adoptively transferred with naive pmel-1 cells alone as control, or vaccinated with gp10025–33 peptide along with poly(I:C) on day 2 only (lymphopenic phase), day 12 only (the restoration phase; the peak of DC expansion), or days 2 and 12 post-CTX treatment. As shown in Fig. 8A, CTX treatment alone significantly (p = 0.001) delayed the tumor growth compared with the PBS-treated tumor bearing mice, and then the tumor rapidly grew afterward. Single vaccination with gp10025–33/poly(I:C) at the lymphopenic phase led to a significant delay (p = 0.038) in the tumor growth as compared with CTX-treated non-vaccinated group, and then the tumor rapidly grew afterward. Interestingly, prime-boost vaccination with gp10025–33/poly(I:C) did not affect the tumor growth in PBS-treated mice, but completely prevented the tumor growth in CTX-treated mice. The degree of tumor growth under each treatment regimen correlate with the rate of survival of each group (Fig. 8B). Interestingly, the antitumor efficacy after prime-boost was further manifested by the development of vitiligo as compared with single vaccination (Fig. 8C).
FIGURE 8
FIGURE 8
Boosting with gp10025–33 peptide/poly(I:C) at the peak of post-CTX DC expansion is essential to establish therapeutic antitumor immunity of naive pmel-1 cells. A, B6 mice (n = 5/group) were challenged s.c. with 2.5 × 105 B16 cells and (more ...)
Although the enhanced antitumor efficacy of pmel-1 cells in the presence of a large pool of activated DCs could be explained by the enhanced expansion (quantity) of pmel-1 cells, the quality of pmel-1 cells might also be enhanced. To evaluate the quality of pmel-1 cells, naive mice were inoculated with B16 cells, treated 7 days later with CTX, received one million pmel-1 cells, and then were vaccinated with gp10025–33/poly(I:C) on day 2 or on days 2 and 12 post-CTX treatment. Mice were killed 5 days later and spleens and LNs were harvested and pooled. Equal numbers (1 × 105) of pmel-1 cells from each group were adoptively transferred into recipient mice (new recipients) challenged 7 days before with s.c. injection of 2 × 105 B16 cells. These new recipients were treated with CTX 1 day before the adoptive transfer of pmel-1 cells. PBS- and CTX-treated controls (with no adoptive T cell therapy) were challenged with B16 cells as controls. Tumor size was recorded at the indicated time points. As shown in Fig. 8D, adoptive transfer of donor cells harvested from the mice vaccinated with gp10025–33/poly(I:C) on days 2 and 12 induced higher antitumor responses than those obtained after adoptive transfer of donor cells harvested from mice vaccinated with gp10025–33/poly(I:C) only on day 2, indicating that the quality of pmel-1 cells generated in the presence of a large pool of activated DCs is a critical mechanism mediating the antitumor responses of the prime-boost vaccination with peptide/poly(I:C). Of note, donor cells harvested from PBS-treated mice vaccinated once or twice with gp10025–33/poly(I:C) could not induce antitumor response in the new recipients (data not shown). In conclusion, these results demonstrate that prime-boost vaccination with peptide/poly(I:C) at both the lymphopenic and restoration phases post-CTX therapy can markedly augment both the quantity and quality of the antitumor efficacy of adoptively transferred CD8+ T cell therapy, perhaps by taking the full advantage of both the lymphopenic microenvironment and the CTX-induced expansion of DCs.
In the present study we observed substantial increases in both the relative and absolute numbers of DCs with an immature phenotype during the restoration phase after CTX-induced lymphodepletion. This observation is consistent with recent studies that reported increases in the number of DCs during the restoration phase in the peripheral blood of cancer patients receiving combinatorial treatment with CTX and the growth factors G-CSF and GM-CSF (4244). Although it was not clear in these studies whether the increase in the frequency of DCs was due solely to the effects induced by CTX or by the growth factors, our results demonstrate that CTX is capable of inducing DC expansion in the peripheral blood in a murine model. The potential clinical significance of our observation is evidenced by the substantial increases in the antitumor efficacy of adoptively transferred CD8+ T cells when these cells were boosted with peptide vaccination and poly(I:C) at the peak of post-CTX DC expansion. These Ag recall responses were markedly abrogated when DCs were depleted during Ag boosting; indicating to the essential contribution of post-CTX expanded DCs.
Despite their immature phenotype, CTX-expanded DCs showed phagocytic (Fig. 2B) and Ag-presenting (Fig. 2C) capabilities, indicating that they are biologically functional. As expected, this post-CTX surge in DCs bearing immature phenotype did not enhance the responses after vaccination with gp10025–33 alone (Fig. 5A). Provision of poly(I:C) at this surge of DCs, however, created an inflammatory microenvironment (TNF-α, MCP-1, IFN-γ, and IL-6) (Fig. 3D), resulting in the appearance of activated CCR7+, CD40+, and CD80+ DCs in LNs (Fig. 3, B and C), which could be contributing to the augmented Ag-specific responses of CD8+ T cells to gp10025–33 peptide when delivered along with poly(I:C) at the peak of DC expansion (Fig. 5A). The appearance of DCs in LNs after poly(I:C) was associated with a significant decrease in the numbers of DCs in the peripheral blood. Given that CCR7 is essential for migration of activated DCs to LNs (40), its up-regulation would suggest that the appearance of DCs in LNs after poly(I:C) treatment is, at least in part, due to their homing from PBL into LNs after maturation. Because resident DCs in LNs express CD8α while migratory DCs do not (41), and because DCs expanded in the blood were CD8α and those increased in LNs were CD8α+, we do not exclude the possibility of local expansion and activation of the resident DCs in LNs of CTX-treated hosts in response to poly(I:C). Alternatively, migratory blood-born DCs may acquire the phenotype of lymphoid (CD8α) DCs upon their arrival to LNs as previously reported (45, 46), and thus become indistinguishable from resident DCs. Regardless of the mechanisms mediating the increase in the number of DCs in LNs, depletion of these cells before boosting of both PBS- and CTX-treated hosts with peptide/poly(I:C) significantly abrogated the expansion of effector pmel-1 cells (Fig. 6), indicating to the importance of DCs to the Ag recall responses of CD8+ T cells to active vaccination in general, and to CTX preconditioning in particular. Similar requirement of DCs to Ag recall responses has been reported in the viral setting (41). Indeed, recent studies by Wang et al. have pointed to the importance of hematopoietic-derived APCs during the lymphopenic phase to the Ag priming of CD8+ T (pmel-1) cells (47). Together, DCs appear to be required during Ag priming and boosting for generation of memory CD8+ T cells.
The expansion of DCs during the restoration phase post-CTX induced lymphodepletion was preceded by the activation of these cells during the lymphopenic phase (Fig. 2A). Indeed, previous reports, including ours, have demonstrated a rapid activation of DCs at the lymphopenic phase after chemotherapy and TBI, associating with significant increases in the Ag-specific responses of adoptively transferred T cells (3, 14, 18, 19, 48, 49). Paulos et al. demonstrated that this rapid DC activation is attributed to the significant damage to the integrity of mucosal barriers and translocation of bacterial products (LPS; a TLR4 ligand) (3). These events would lead to induction of inflammatory cytokines (8, 9, 38) and activation of DCs. Therefore, the transient activation of DCs during the lymphopenic phase (up to day 4) after CTX treatment may be because of the rapid clearance of LPS from circulation. There is further evidence that exogenous LPS can substitute for the endogenous TBI-induced LPS for augmentation of the antitumor responses of CD8+ T cells to active vaccination when they were adoptively transferred to immune cell (NK cells and CD4 T cells)-ablated recipient mice (3). Similarly, we have reported that addition of poly(I:C) to OVAp vaccination during the lymphopenic phase after CTX preconditioning markedly augmented CD8+ T cell expansion, which was associated with significant activation of DCs in spleen and liver (14). In the present study, we were able to extend this observation by showing the capability of poly(I:C) to induce activation of DCs expanded during the restoration phase, resulting in robust increases in the CD8+ T cell responses to active vaccination (Fig. 5, A and B). Taken together, we would suggest that the host microenvironment created after induction of lymphodepletion can be successfully exploited both at the lymphopenic and restoration phases by TLRL (e.g., TLR3L and TLR4L) to benefit adoptive T cell therapy combined with active vaccination.
The activation of DCs during the lymphopenic phase and their expansion during the restoration phase may suggest a harmonized hierarchy of multiple mechanisms involved in the beneficial effect of CTX on adoptive T cell therapy. This hierarchy warrants the reconsideration of the timing between adoptive T cell transfer into a CTX-lymphodepleted host and any subsequent vaccinations. We tested this hypothesis by applying prime-boost vaccination with gp10025–33/poly(I:C) at the lymphopenic and restoration phases, so that pmel-1 cells could benefit from the activated DCs at the lymphopenic phase as well as from the activated large pool of DCs at the restoration phase. This regimen induced a substantial expansion of pmel-1 cells and prevention of B16 tumor growth (Fig. 8), which absolutely required CTX treatment because the same prime-boost regimen in PBS-treated mice could not prevent B16 tumor growth. Our results point to the role of post-CTX expanded DCs in this antitumor effects of pmel-1 cells because boosting of the CTX-treated mice with gp10025–33/poly(I:C) at the peak of DC expansion resulted in recruitment of activated DCs in LNs and spleen (Fig. 5B), increases in the numbers (quantity) of the Ag-specific pmel-1 cells in LNs and spleen (Fig. 5D), and tumor regression and better survival (Fig. 8). These results suggest that tumor regression was mediated by pmel-1 cells expansion in the presence of a large pool of activated DCs. Because DCs were required for pmel-1 cell expansion (Fig. 7D), our results suggest that DCs are important for the antitumor effects of pmel-1 cells by augmenting the quantity of the latter. DCs might also play a role in the tumor regression by augmenting the quality of the Ag-specific pmel-1 cells because adoptive transfer of donor cells harvested from mice vaccinated with gp10025–33/poly(I:C) on days 2 and 12 induced higher antitumor responses than those harvested from mice vaccinated with gp10025–33/poly(I:C) only on day 2. Thus, we suggest that the presence of a large pool of activated DCs augment both the quantity and quality of the tumor-specific responses of pmel-1 cells.
Recent studies have also reported the capability of naive and effector gp10025–33-specific pmel-1 cells to induce regression of established B16 tumor. The antitumor effects in these studies, however, required aggressive treatment protocols consisting of TBI-induced lymphodepletion or myelodepletion followed by hematopoietic stem cell transplant, adoptive transfer of in vitro cytokine-conditioned Ag-stimulated pmel-1 cell, vaccination with 2 × 107 plaque forming units of a recombinant fowlpox virus encoding gp10025–33 or with repeated ex vivo vaccination with peptide-pulsed DCs, and exogenous administration of high doses of IL-2 (4, 47, 50). In addition to these established therapeutically effective antitumor regimens, our data presents another therapeutically effective antitumor regimen based on targeting a large pool of DCs by TLRLs during peptide vaccination, obviating the need for more complicated and potentially toxic treatment regimens such as IL-2 therapy.
We believe that our in vivo DC-based prime-boost vaccination with peptide/TLR3L at defined phases post-lymphodepletion is an effective treatment approach because it induces in vivo maturation of DCs by TLRLs, which, in contrast to ex vivo DC-based vaccination, also stimulate other critical factors in the host microenvironment. In line with this notion, several recent studies reported substantial improvement in T cell responses to active vaccination and generation of efficacious antitumor responses upon in vivo activation of Flt3L-mobilized DCs with TLRLs, in particular the TLR9L CpG (5155). In conclusion, our data showed that CTX therapy induces a biphasic effect on DCs. During the lymphopenic phase, DCs are activated, while during the restoration phase DCs are expanded but express immature phenotype, which can be exploited in vivo to favor generation of robust antitumor immunity against self-tumor Ag. Our data provide a useful foundation for a rationale design of anti-cancer immunotherapy regimens by combining lymphodepletion, adoptive T cell therapy, and TLRL-based tumor vaccines.
Acknowledgments
We thank Dr. Michael Nishimura for the critical revision of the manuscript, Drs. Narender Nath and Yian Chen for technical support, and Mr. Rick Peppler for technical support in flow cytometry.
Footnotes
1This work was supported by the National Institutes of Health Grant 1 R01 CA94856-01.
3Abbreviations used in this paper: TBI, total body irradiation; BM, bone marrow; cDC, conventional DC; CTX, cyclophosphamide; DC, dendritic cell; DTx, diphtheria toxin; DTR, diphtheria toxin receptor; LN, lymph node; OVAp, OVA albumin peptide; PBL, peripheral blood leukocyte; pDC, plasmacytoid DC; Tg, transgenic; TLRL, TLR ligand; TLR3L, TLR 3 ligand.
4The online version of this article contains supplemental material.
Disclosures
The authors have no financial conflict of interest.
1. Wrzesinski C, Restifo NP. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr. Opin. Immunol. 2005;17:195–201. [PMC free article] [PubMed]
2. Gattinoni L, Powell DJ, Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 2006;6:383–393. [PMC free article] [PubMed]
3. Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, Palmer DC, Boni A, Muranski P, Yu Z, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J. Clin. Invest. 2007;117:2197–2204. [PMC free article] [PubMed]
4. Wrzesinski C, Paulos CM, Gattinoni L, Palmer DC, Kaiser A, Yu Z, Rosenberg SA, Restifo NP. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J. Clin. Invest. 2007;117:492–501. [PMC free article] [PubMed]
5. Rosenberg SA, Yang JC, Robbins PF, Wunderlich JR, Hwu P, Sherry RM, Schwartzentruber DJ, Topalian SL, Restifo NP, Filie A, Chang R, Dudley ME. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J. Immunother. 2003;26:385–393. [PMC free article] [PubMed]
6. Protheroe AS, Pickard C, Johnson PW, Craddock T, Shefta J, Short K, Lancaster F, Selby PJ, Henwood J, Boylston AW. Persistence of clonal T-cell expansions following high-dose chemotherapy and autologous peripheral blood progenitor cell rescue. Br. J. Haematol. 2000;111:766–773. [PubMed]
7. Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005;26:111–117. [PMC free article] [PubMed]
8. Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, Baccarini S, Maccari S, Ramoni C, Belardelli F, Proietti E. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin. Cancer Res. 2007;13:644–653. [PubMed]
9. Schiavoni G, Mattei F, Di Pucchio T, Santini SM, Bracci L, Belardelli F, Proietti E. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood. 2000;95:2024–2030. [PubMed]
10. Awwad M, North RJ. Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour: evidence that Cy permits the expression of adoptive T- cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology. 1988;65:87–92. [PubMed]
11. Hoover SK, Barrett SK, Turk TM, Lee TC, Bear HD. Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity. Cancer Immunol. Immunother. 1990;31:121–127. [PubMed]
12. Ikezawa Y, Nakazawa M, Tamura C, Takahashi K, Minami M, Ikezawa Z. Cyclophosphamide decreases the number, percentage and the function of CD25(+) CD4(+) regulatory T cells, which suppress induction of contact hypersensitivity. J. Dermatol. Sci. 2005;39:105–112. [PubMed]
13. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 2005;202:907–912. [PMC free article] [PubMed]
14. Salem ML, Kadima AN, El-Naggar SA, Rubinstein MP, Chen Y, Gillanders WE, Cole DJ. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J. Immunother. 2007;30:40–53. [PubMed]
15. Mihalyo MA, Doody AD, McAleer JP, Nowak EC, Long M, Yang Y, Adler AJ. In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy. J. Immunol. 2004;172:5338–5345. [PMC free article] [PubMed]
16. Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, Venditti M, Carlei D, Belardelli F. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J. Clin. Invest. 1998;101:429–441. [PMC free article] [PubMed]
17. Lou Y, Wang G, Lizee G, Kim GJ, Finkelstein SE, Feng C, Restifo NP, Hwu P. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res. 2004;64:6783–6790. [PMC free article] [PubMed]
18. Limpens J, Van Meijer M, Van Santen HM, Germeraad WT, Hoeben-Schornagel K, Breel M, Scheper RJ, Kraal G. Alterations in dendritic cell phenotype and function associated with immunoenhancing effects of a subcutaneously administered cyclophosphamide derivative. Immunology. 1991;73:255–263. [PubMed]
19. Phipps RP, Mandel TE, Schnizlein CT, Tew JG. Anamnestic responses induced by antigen persisting on follicular dendritic cells from cyclophosphamide-treated mice. Immunology. 1984;51:387–397. [PubMed]
20. Salem ML, Kadima AN, Cole DJ, Gillanders WE. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J. Immunother. 2005;28:220–228. [PubMed]
21. Kato M, Neil TK, Fearnley DB, McLellan AD, Vuckovic S, Hart DN. Expression of multilectin receptors and comparative FITC-dextran uptake by human dendritic cells. Int. Immunol. 2000;12:1511–1519. [PubMed]
22. Salem ML, Kadima AN, Zhou Y, Nguyen CL, Rubinstein MP, Demcheva M, Vournakis JN, Cole DJ, Gillanders WE. Paracrine release of IL-12 stimulates IFN-γ production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine. J. Immunol. 2004;172:5159–5167. [PubMed]
23. Pelaez B, Campillo JA, Lopez-Asenjo JA, Subiza JL. Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism. J. Immunol. 2001;166:6608–6615. [PubMed]
24. Jung S, Unutmaz D, Wong P, Sano G, De los Santos K, Sparwasser T, Wu S, Vuthoori S, Ko K, Zavala F, et al. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity. 2002;17:211–220. [PMC free article] [PubMed]
25. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105:2862–2868. [PubMed]
26. O’Keeffe M, Hochrein H, Vremec D, Scott B, Hertzog P, Tatarczuch L, Shortman K. Dendritic cell precursor populations of mouse blood: identification of the murine homologues of human blood plasmacytoid pre-DC2 and CD11c+ DC1 precursors. Blood. 2003;101:1453–1459. [PubMed]
27. Suto A, Nakajima H, Tokumasa N, Takatori H, Kagami S, Suzuki K, Iwamoto I. Murine plasmacytoid dendritic cells produce IFN-γ upon IL-4 stimulation. J. Immunol. 2005;175:5681–5689. [PubMed]
28. Adachi Y, Toki J, Ikebukuro K, Tomita M, Kaneda H, Tanabe A, Jun L, Minamino K, Suzuki Y, Taketani S, Ikehara S. Immature dendritic cells (CD11c+ CD3− B220− cells) present in mouse peripheral blood. Immunobiology. 2002;206:354–367. [PubMed]
29. Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, Muranski P, Sanchez-Perez L, Palmer DC, Yu Z, et al. Toll-like receptors in tumor immunotherapy. Clin. Cancer Res. 2007;13:5280–5289. [PMC free article] [PubMed]
30. Sapoznikov A, Fischer JA, Zaft T, Krauthgamer R, Dzionek A, Jung S. Organ-dependent in vivo priming of naive CD4+, but not CD8+, T cells by plasmacytoid dendritic cells. J. Exp. Med. 2007;204:1923–1933. [PMC free article] [PubMed]
31. Datta SK, Redecke V, Prilliman KR, Takabayashi K, Corr M, Tallant T, DiDonato J, Dziarski R, Akira S, Schoenberger SP, Raz E. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J. Immunol. 2003;170:4102–4110. [PubMed]
32. Lore K, Betts MR, Brenchley JM, Kuruppu J, Khojasteh S, Perfetto S, Roederer M, Seder RA, Koup RA. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J. Immunol. 2003;171:4320–4328. [PubMed]
33. Ida JA, Shrestha N, Desai S, Pahwa S, Hanekom WA, Haslett PA. A whole blood assay to assess peripheral blood dendritic cell function in response to Toll-like receptor stimulation. J. Immunol. Methods. 2006;310:86–99. [PubMed]
34. Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, Miller JF, Liau LM. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J. Immunol. 2006;176:157–164. [PubMed]
35. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immun. 2005;6:769–776. [PMC free article] [PubMed]
36. Warger T, Osterloh P, Rechtsteiner G, Fassbender M, Heib V, Schmid B, Schmitt E, Schild H, Radsak MP. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood. 2006;108:544–550. [PubMed]
37. Doxsee CL, Riter TR, Reiter MJ, Gibson SJ, Vasilakos JP, Kedl RM. The immune response modifier and Toll-like receptor 7 agonist S-27609 selectively induces IL-12 and TNF-α production in CD11c+CD11b+ CD8− dendritic cells. J. Immunol. 2003;171:1156–1163. [PubMed]
38. Salem ML, El-Naggar SA, Kadima A, Gillanders WE, Cole DJ. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine. 2006;24:5119–5132. [PubMed]
39. Salem ML, Kadima AN, EL-Naggar S, Rubinstein MP, Gillanders WE, Cole DJ. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8 T cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J. Immunother. 2007;30:40–53. [PubMed]
40. Sánchez-Sánchez N, Riol-Blanco L, Rodríguez-Fernández JL. The multiple personalities of the chemokine receptor CCR7 in dendritic cells. J. Immunol. 2006;176:5153–5159. [PubMed]
41. Carbone FR, Belz GT, Heath WR. Transfer of antigen between migrating and lymph node-resident DCs in peripheral T-cell tolerance and immunity. Trends Immunol. 2004;25:655–658. [PubMed]
42. Vuckovic S, Kim M, Khalil D, Turtle CJ, Crosbie GV, Williams N, Brown L, Williams K, Kelly C, Stravos P, et al. Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expression. Blood. 2003;101:2314–2317. [PubMed]
43. Gazitt Y, Akay C, Thomas C., 3rd No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of nonhodgkin’s lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF. Stem Cells Dev. 2006;15:269–277. [PubMed]
44. Radcliff FJ, Caruso DA, Koina C, Riordan MJ, Roberts AW, Tang ML, Baum CM, Woulfe SL, Ashley DM. Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy. Br. J. Haematol. 2002;119:204–211. [PubMed]
45. Liu K, Waskow C, Liu X, Yao K, Hoh J, Nussenzweig M. Origin of dendritic cells in peripheral lymphoid organs of mice. Nat. Immunol. 2007;8:578–583. [PubMed]
46. Kabashima K, Banks TA, Ansel KM, Lu TT, Ware CF, Cyster JG. Intrinsic lymphotoxin-β receptor requirement for homeostasis of lymphoid tissue dendritic cells. Immunity. 2005;22:439–450. [PubMed]
47. Wang LX, Li R, Yang G, Lim M, O’Hara A, Chu Y, Fox BA, Restifo NP, Urba WJ, Hu HM. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res. 2005;65:10569–10577. [PMC free article] [PubMed]
48. Torihata H, Ishikawa F, Okada Y, Tanaka Y, Uchida T, Suguro T, Kakiuchi T. Irradiation up-regulates CD80 expression through two different mechanisms in spleen B cells, B lymphoma cells, and dendritic cells. Immunology. 2004;112:219–227. [PubMed]
49. Zhang Y, Louboutin JP, Zhu J, Rivera AJ, Emerson SG. Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease. J. Clin. Invest. 2002;109:1335–1344. [PMC free article] [PubMed]
50. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA, Waldmann TA, Restifo NP. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. USA. 2005;102:9571–9576. [PubMed]
51. Merad M, Sugie T, Engleman EG, Fong L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood. 2002;99:1676–1682. [PubMed]
52. Cornet S, Menez-Jamet J, Lemonnier F, Kosmatopoulos K, Miconnet I. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope. Vaccine. 2006;24:1880–1888. [PubMed]
53. Krug A, Rothenfusser S, Selinger S, Bock C, Kerkmann M, Battiany J, Sarris A, Giese T, Speiser D, Endres S, Hartmann G. CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells. J. Immunol. 2003;170:3468–3477. [PubMed]
54. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JC. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med. 1997;3:625–631. [PubMed]
55. Furumoto K, Soares L, Engleman EG, Merad M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J. Clin. Invest. 2004;113:774–783. [PMC free article] [PubMed]